Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment

Annals of Surgery

Volumn 212, Issue 1, 1990, Pages 87-96

  El Sanadiki, Mostafa N ^a   Simon Cross, K ^a   Murray, John J ^a,b   Schuman, Robert W ^a   Mikat, Eileen ^a   McCann, Richard L ^a   Hagen, Per Otto ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; GRAFT PATENCY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR SMOOTH MUSCLE; VEIN GRAFT;

ANIMAL; BLOOD PRESSURE; CAROTID ARTERIES; CHOLESTEROL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERPLASIA; JUGULAR VEINS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION; RABBITS; SUPPORT, U.S. GOV'T, P.H.S.; VEINS; VERAPAMIL;

EID: 0025283061     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199007000-00012     Document Type: Article

References (40)

1. Conti CR, Pepine CJ, Feldman RL, Hill JA. Calcium antagonists. Cardiology 1985; 72:297-321.
2. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981; 68:1366-1369.
3. Slender S, Ravn H, Haugegaard M, Kjeldsen K. Effect of verapamil on accumulation of free and esterified cholesterol in the thoracic aorta of cholesterol-fed rabbits. Atherosclerosis 1986; 61:15-23.
4. Sugano M, Nakashima Y, Matsushima T, et al. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Arteriosclerosis 1986; 6:237-241.
5. Ginsburg R, Davis K, Bristow MR, et al. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest 1983; 49:154-158.
6. El-Sanadiki MN, Cross KS, Mikat EM, Hagen P-O. Verapamil therapy reduces intimal hyperplasia in balloon injured rabbit aorta. Circulation 1987; 76(Suppl):314.
7. Jackson CL, Bush RC, Bowyer DE. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis 1988; 69:115-122.
8. Nomoto A, Hirosumi J, Sekiguchi C, et al. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Atherosclerosis 1987; 64:255-261.
9. Handley DA, Van Valen RG, Melden MK, Saunders RN. Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol 1986; 124:88-93.
10. Bush HL, Jackubowski JA, Curl GR, et al. The natural history of endothelial structure and function in arterialized vein grafts. J Vase Surg 1986; 3:204-215.
11. Grondin CM, Campeau L, Lesperance J, et al. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984; 70(Suppl I):208-212.
12. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295:369-377.
13. Verstraete M, Brown BG, Chesebro JH, et al. Evaluation of anti-platelet agents in the prevention of aorto-coronary bypass occlusion. Eur Heart J 1986; 7:4-13.
14. Gundry SR, Jones M, Ishihara T, Ferrans VJ. Intraoperative trauma to human saphenous veins: scanning electron microscopic comparison of preparation techniques. Ann Thorac Surg 1980; 30: 40-47.
15. Okumura K, Yasue H, Horio Y, et al. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation 1988; 77:535-542.
16. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314:488-500.
17. Stein O, Halperin G, Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis 1987; 7:585-592.
18. Nakao J, Ito H, Ooyama T, et al. Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid. Atherosclerosis 1983; 46:309-319.
19. Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. Am J Cardiol 1987; 59:163B-172B.
20. Habib JB, Bossaller C, Wells S, et al. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res 1986; 58: 305-309.
21. Long CJ, Stone TW. The release of endothelium-derived relaxant factor is calcium dependent. Blood Vessels 1985; 22:205-208.
22. Harapat SR, Kates RE. Rapid high-pressure liquid chromotographic analysis of verapamil in blood and plasma. J Chromatogr Biomed Appl 1979; 170:385-390.
23. Chiamori N, Henry RJ. Study of the Jerric Chloride Method for determination of Total Cholesterol and Cholesterol Esters. Am J Clin Pathol 1959; 31:305-309.
24. Murray JJ, Fridovich I, Makhoul RG, Hagen P-O. Stabilization and partial characterization of endothelium-derived relaxing factor from cultured bovine endothelial cells. Biochem Biophys Res Comm 1986; 141:689-696.
25. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
26. Stein O, Leitersdorf E, Stein Y. Verapamil enhances receptor-medialed endocytosis of low density lipoproteins by aortic cells in culture. Arteriosclerosis 1985; 5:35-44.
27. Etingin OR, Hajjar DP. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. J Clin Invest 1985; 75:1554-1558.
28. Blumlein SL, Sievers R, Kidd P, Parmley WW. Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am J Cardiol 1984; 54:884-889.
29. Groves HM, Kinlough-Rathbone RL, Mustard JF. Development of non-thrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis 1986; 6:189-195.
30. Srivastava KC. Effects of dipyridamole, nifedipine, verapamil, hydralazine and propanolol on the formation of prostacyclin and thromboxane in a coupled system of platelets and aorta. Prostaglandins Leukotrienes Med 1986; 23:31-36.
31. Ikeda Y, Kikuchi M, Toyama K, et al. Inhibition of human platelet functions by verapamil. Thromb Haemost 1981; 45:158-161.
32. Han P, Boatwright C, Ardlie NG. Verapamil and collagen-induced platelet reactions: evidence for a role for intracellular calcium in platelet activation. Thromb Haemost 1983; 50:537-540.
33. Barnathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet alpha-adrenergic receptors. Am J Physiol 1982; 242:H19-H23.
34. Glossman H, Hornung R. Calcium- and potassium-channel blockers interact with alpha-adrenoceptors. Mol Cell Endocrinol 1980; 19:243-251.
35. 1-adrenergic and muscarinic but not beta-adrenergic receptors in rat myocardium. J Cardiovasc Pharmacol 1982; 4: 515-520.
36. Berridge MJ. Receptors and calcium signalling. Trends Pharmacol Sci 1980; 1:419-424.
37. Nilsson J, Sjolund M, Palmberg L, et al. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 1985; 58:109-122.
38. 3H-thymidine incorporation by vascular smooth muscle cells in vitro. Can J Clin Invest 1988; 11:62-67.
39. Cole CW, Hagen P-O, Lucas JF, et al. Association of polymorphonuclear leukocytes with sites of aortic-catheter-induced injury in rabbits. Atherosclerosis 1987; 67:229-236.
40. Steiner RD, Pratt A, Busse WW. Cytochalasin B facilitates the inhibition of human polymorphonuclear leukocyte generation of superoxide by verapamil. J Lab Clin Med 1984; 103:949-958.